M. Mazier

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

Eric Van Cutsem, Fernando Rivera, Scott Berry et al. · Annals of Oncology · 2009 · 534 citations

Medicine, Oncology, Pharmacotherapy +10

Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC—First B.E.A.Trial

Scott Berry, David Cunningham, M. Michael et al. · Journal of Clinical Oncology · 2006 · 42 citations

Medicine, Oncology, Pharmacotherapy +10

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

Meletios Α. Dimopoulos, Meral Beksaç, Lotfi Benboubker et al. · Haematologica · 2013 · 39 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT

Scott Berry, Eric Van Cutsem, Albrecht Kretzschmar et al. · Journal of Clinical Oncology · 2008 · 22 citations

Medicine, Oncology, Pharmacology +15

Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrial

Albrecht Kretzschmar, Eric Van Cutsem, M. Michael et al. · Journal of Clinical Oncology · 2007 · 19 citations

Medicine, Oncology, Pharmacology +12